| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.077 | 0.03 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.076 | 0.03 |
| mRNA | FSC231 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.04 |
| mRNA | bafilomycin A1 | CTRPv2 | pan-cancer | AAC | -0.29 | 0.04 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | 0.072 | 0.04 |
| mRNA | itraconazole | CTRPv2 | pan-cancer | AAC | 0.078 | 0.04 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.11 | 0.04 |
| mRNA | neopeltolide | CTRPv2 | pan-cancer | AAC | -0.14 | 0.04 |
| mRNA | NSC23766 | CTRPv2 | pan-cancer | AAC | 0.069 | 0.05 |
| mRNA | navitoclax:PLX-4032 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.07 | 0.05 |